ITA6606
ITA6606
- Catalog: ITA6606
- Gene/Protein: CD274
- Product Description: Immunotag™ CD274 Antibody
385.0000
Price in reward points: 385
Your shopping cart is empty!
Antibody Specification | |
Datasheet | |
Target Protein | CD274 |
Clonality | Polyclonal |
Storage/Stability | -20°C/1 year |
Application | WB,IHC,ELISA |
Recommended Dilution | WB 1:500-1:2000 IHC 1:50-1:200 |
Concentration | 1 mg/ml |
Reactive Species | Human,Mouse,Rat |
Host Species | Rabbit |
Immunogen | A synthesized peptide derived from human CD274 |
Specificity | CD274 Antibody detects endogenous levels of total CD274 |
Purification | The antiserum was purified by peptide affinity chromatography. |
Form | Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt |
Gene Name | CD274 |
Accession No. | Q9NZQ7 |
Alternate Names | B7 H; B7 H1; B7 homolog 1; B7-H1; B7H; B7H1; CD 274; CD274; CD274 antigen; CD274 molecule; MGC142294; MGC142296; OTTHUMP00000021029; PD L1; PD-L1; PD1L1_HUMAN; PDCD1 ligand 1; PDCD1L1; PDCD1LG1; PDL 1; PDL1; Programmed cell death 1 ligand 1; Programmed death ligand 1; RGD1566211; |
Description | Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (PubMed:28813417, PubMed:28813410). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077). |
Cell Pathway/ Category | Primary Polyclonal Antibody |
Protein MW | 33kDa |
Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |